Du är här

2017-08-29

AstraZeneca: AstraZeneca and Takeda establish collaboration to develop and commercialise MEDI1341 for Parkinson's disease

AstraZeneca and Takeda Pharmaceutical Company Limited today announced
that they have entered an agreement to jointly develop and
commercialise MEDI1341, an alpha-synuclein antibody currently in
development as a potential treatment for Parkinson's disease (PD).

Alpha-synuclein (?-synuclein) is an aggregation-prone protein that
contributes to the development of PD. This protein is the major
constituent of Lewy bodies, which are pathological protein aggregates
that accumulate in the nerve cells of patients with PD and appear to
spread throughout the nervous system during the progression of the
disease. These insights support the development of new PD medicines
that seek to remove existing pathological alpha-synuclein aggregates,
prevent their formation, or stop them from spreading. Such therapies
could potentially prevent or delay the onset of PD, or halt or slow
its progression.

MEDI1341 is an antibody that is differentiated by its high affinity,
high selectivity and reduced effector function (lower interaction
with the immune system), which has the potential to achieve a better
efficacy and safety profile than other alpha-synuclein antibodies.
MEDI1341 is due to enter Phase I clinical trials later this year.

Mene Pangalos, Executive Vice President, Innovative Medicines & Early
Development Biotech Unit and Global Business Development at
AstraZeneca, said: "Today there are no medicines that can slow or
halt the degenerative progress of Parkinson's disease so this remains
a large area of unmet medical need. Takeda has an excellent track
record in neuroscience research and we are excited to be working
together. By combining our scientific expertise and sharing the risks
and cost of development, we hope to accelerate the advancement of
MEDI1341 as a promising new approach to support the treatment of
people with Parkinson's disease around the world."

Emiliangelo Ratti, Head, Global CNS Therapeutic Area Unit, Takeda,
said: "Despite modest advancements in maintenance therapies,
Parkinson's disease continues to represent a devastating diagnosis
and a burdensome challenge for therapeutic discovery. Our
collaboration with AstraZeneca is a sophisticated one that will
enable us to efficiently advance a validated target in a new
modality, with the aim of improving the lives of patients."

Contractual and financial considerations

Under the terms of the agreement, AstraZeneca will lead Phase I
development while Takeda will lead future clinical development
activities. The companies will share equally future development and
commercialisation costs for MEDI1341, as well as any future revenues.
Takeda will pay AstraZeneca up to $400 million, including initial
revenue in 2017 and development and sales milestones thereafter.
Additional terms of the agreement are not disclosed.

- ENDS -

NOTES TO EDITORS

About Parkinson's disease

Parkinson's disease is the second most common neurodegenerative
disease, after Alzheimer's disease.[1]
(http://file:///C:/Users/kdzn235/AppData/Local/Microsoft/Windows/Temporar...)
An estimated seven to ten million people worldwide are living with
Parkinson's disease. The combined direct and indirect cost of
Parkinson's, including treatment, social security payments and lost
income from inability to work, is estimated to be nearly $25 billion
per year in the United States alone.[2]
(http://file:///C:/Users/kdzn235/AppData/Local/Microsoft/Windows/Temporar...)

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that
focuses on the discovery, development and commercialisation of
prescription medicines, primarily for the treatment of diseases in
three therapy areas - Oncology, Cardiovascular & Metabolic Diseases
and Respiratory. The Company also is selectively active in the areas
of autoimmunity, neuroscience and infection. AstraZeneca operates in
over 100 countries and its innovative medicines are used by millions
of patients worldwide.

For more information, please visit www.astrazeneca.com and follow us
on Twitter @AstraZeneca.

Media
Relations
Esra Erkal UK/Global +44 203 749 5638
-Paler
Rob UK/Global +44 203 749 5821
Skelding
Karen UK/Global +44 203 749 5634
Birmingham
Matt Kent UK/Global +44 203 749 5906
Jacob Lund Sweden +46 8 553 260 20
Michele US +1 302 885 2677
Meixell

Investor
Relations
Thomas +44 203 749 5712
Kudsk
Larsen
Craig Finance, Fixed Income, M&A +44 7881 615 764
Marks
Henry Oncology +44 203 749 5797
Wheeler
Mitchell Oncology +1 240 477 3771
Chan
Christer Diabetes; Autoimmunity, Neuroscience & Infection +44 203 749 5711
Gruvris
Nick Stone Respiratory; Brilinta +44 203 749 5716
US toll +1 866 381 7277
free

----------------------------------------------------------------------

[1]
(http://file:///C:/Users/kdzn235/AppData/Local/Microsoft/Windows/Temporar...)
https://www.niehs.nih.gov/research/supported/health/neurodegenerative/in...

[2]
(http://file:///C:/Users/kdzn235/AppData/Local/Microsoft/Windows/Temporar...)
http://www.pdf.org/parkinson_statistics

-----------------------------------------------------------
http://news.cision.com/se/astrazeneca/r/astrazeneca-and-takeda-establish...

Författare Cision

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.